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Abstract
Background: The urokinase plasminogen activating system (uPAS) is implicated in neoplastic progression and high 
tissue levels of uPAS components correlate with a poor prognosis in different human cancers. Despite that, relative few 
studies are available on the expression and function of the uPAS components in human seminomas. In the present 
study we characterized the expression of the urokinase plasminogen activator (uPA), its cognate receptor (uPAR) and 
the uPA inhibitors PAI-1 and PAI-2 in normal human testis and seminomas.
Methods: The expression of the above genes was evaluated by means of quantitative RT-PCR, western blot, 
zymographic analysis and immunohistochemistry.
Results: Quantitative RT-PCR analysis of 14 seminomas demonstrated that uPA and uPAR mRNAs were, with respect to 
control tissues, increased in tumor tissues by 3.80 ± 0.74 (p < 0.01) and 6.25 ± 1.18 (p < 0.01) fold, respectively. On the 
other hand, PAI-1 mRNA level was unchanged (1.02 ± 0.24 fold), while that of PAI-2 was significantly reduced to 0.34 ± 
0.18 (p < 0.01) fold. Western blot experiments performed with protein extracts of three seminomas and normal tissues 
from the same patients showed that uPA protein levels were low or undetectable in normal tissues and induced in 
tumor tissues. On the same samples, zymographic analysis demonstrated increased uPA activity in tumor tissue 
extracts. Western blot experiments showed that also the uPAR protein was increased in tumor tissues by 1.83 ± 0.15 
fold (p < 0.01). The increased expression of uPA and uPAR was further confirmed by immunohistochemical staining 
performed in 10 seminomas and autologous uninvolved peritumoral tissues. Finally, variation in the mRNA level of PAI-
1 significantly correlated with tumor size.
Conclusions: We demonstrated the increased expression of uPA and uPAR in human seminomas with respect to 
normal testis tissues, which may be relevant in testicular cancer progression.
Background
The term "germ cell tumors" refers to a heterogeneous
group of neoplasms originating from cells belonging to
the germ cell lineage [1-3]. They occur mainly in the
gonad, but also in specific extragonadal sites along the
migration route of primordial germ cells. In the human,
testis germ cell tumors comprise three main entities char-
acterized by different epidemiological, histological and
clinical parameters. The first includes the teratomas-yolk
sac tumors usually taking place during the first years of
life; the second includes the testicular germ cell tumors
(TGCT) and consists of seminoma and non-seminoma
cancers taking place following puberty and during the
adult life; the last is represented by the spermatocytic
seminomas which become manifest in elderly men [2,3].
Although germ cell tumors are rare in the male popula-
tion, accounting for less than 1% of all cancers, the TGCT
is the most common malignancy in young adult cauca-
sian males [3,4]. Overt TGCT is thought to generate from
a precursor neoplastic lesion defined as intratubular
germ cell neoplasia (IGCN) [3,5,6]. The malignant pro-
gression of the IGCN, characterized by extratubular inva-
sion, is thought to be an active process requiring the
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breakdown of the extracellular matrix (ECM) and the
basement membrane (BM) surrounding the seminiferous
tubules [3].
The urokinase plasminogen activating system (uPAS)
consists of the urokinase plasminogen activator (uPA),
the glycolipid-anchored cell membrane receptor for the
uPA (uPAR) and four serin protease inhibitors (SERPIN),
the plasminogen activator inhibitor 1 (PAI-1 or
SERPINE1) and 2 (PAI-2 or SERPINB2), the protein C
inhibitor (PAI-3 or SERPINA5) and the nexin-1
(SERPINE2) [7-13]. The uPAS is involved in many physi-
ological functions and, along with members of the matrix
metalloproteinases (MMPs) family, it has been implicated
in cancer invasion and metastatization, in which by
degrading ECM and BM allows local diffusion and spread
to distant sites of malignant cells [7,8,11,14-17]. A grow-
ing number of experimental evidences indicates that the
uPAS also affects tumor cell proliferation, migration,
adhesion, intravasation and extravasation as well as
tumor angiogenesis [8,11,16-21]. The role of uPAS in
human cancer progression is further supported by clini-
cal evidences demonstrating that high tissue levels of its
components correlate with a poor prognosis in different
types of cancer [22-24]. This is particularly evident in
breast cancer, in which uPA and PAI-1 have been shown
to be among the most potent prognostic factors
described to date, with a predictive value stronger than
those of patient age, tumor size, estrogen and progester-
one receptors, HER-2/neu or p53 expression [17,23-25].
In patients with breast cancer as well as with other types
of malignancies, paradoxically, high levels of PAI-1 are
also associated with an adverse outcome [10,23-25]. In
particular, it has been proposed that high levels of PAI-1
may promote cancer progression in several ways, that is
by inhibiting cell adhesions, stimulating cancer cell motil-
ity, promoting tumor angiogenesis and preventing an
excessive ECM proteolysis by plasmin that could prevent
cellular migration [8,10,11,19-21]. In view of their prog-
nostic value, both uPA and PAI-1 are candidate molecular
markers for clinical use in patients with breast cancer
[8,11]. Moreover, the involvement of uPAS at multiple
steps during the neoplastic evolution represents an
attractive target for anti-cancer therapy, and a number of
studies aimed either to inhibit uPA expression, catalytic
activity or to prevent its binding to uPAR have been per-
formed with success on animals, while the results of trials
in human cancers are awaited [11,22,26].
To date very few information on the expression of the
different uPAS components during the progression of
TGCT are available [3,27,28]. In the present study we
characterized the expression patterns of uPA, uPAR, PAI-
1 and PAI-2 in seminomas tissues in comparison to those
present in normal testicular tissues obtained following
orchidectomy.
Methods
Materials
Trizol® reagent, oligo(dT)12-18 primer 0,5 μg/μl and M-
MLV reverse transcriptase were purchased from Invitro-
gen (Carlsbad, CA). All the primers were from Primm
(Milano, Italy). Bovine casein, human plasminogen,
sodium deoxycholate, aprotinin, leupeptin, phenylmeth-
ylsulfonyl fluoride, sodium orthovanadate and sodium
pyrophosphate were provided from Sigma Chemical Co.
(St. Louis, MO). Bradford protein assay kit and electro-
phoresis reagents were obtained from Bio-Rad Laborato-
ries (Hercules, CA). Monoclonal antibodies against
urokinase plasminogen activator B-chain (uPA) and its
receptor (uPAR) were purchased from the American
Diagnostica Inc. (Stamford, CT). The monoclonal anti-
body against actin and the human urokinase native from
urine were obtained from Immunological Sciences
(Roma, Italy). The anti-mouse peroxidase-conjugated
antibody and the SuperSignal chemiluminescent sub-
s t r a t e  w e r e  f r o m  P i e r c e  ( R o c k f o r d ,  I L ) .  T h e  F a s t S t a r t
DNA MasterPLUS  SYBR Green I kit was from Roche
Applied Sciences (Mannheim, Germany). Perfectprep®
Gel Cleanup Kit was obtained from Eppendorf (Ham-
burg, Germany).
Normal and tumoral human testicular tissues
Fragments of normal and tumoral testicular tissues were
obtained following orchidectomy of patients (age ranging
from 24 to 47 years) affected by seminoma treated at the
Regina Elena Cancer Institute (Rome). All patients gave
their informed consent and the study was approved by
the ethical committee of the Regina Elena Cancer Insti-
tute. Tissue samples were immediately frozen in liquid
nitrogen, stored at -80°C and then used for the prepara-
tion of total RNA. In addition, some cDNAs prepared
from normal human testis and seminoma tissues were
obtained from BioChain Institute, Inc. (Hayward, CA). In
total, 14 cases of seminomas and 6 normal human testic-
ular tissues were analyzed (Table 1). Protein extracts were
also available from three seminomas and normal matched
tissues,  i.e.  normal tissues surrounding the neoplastic
lesions obtained from the same patients, and prepared as
below described. Finally, 10 paraffin-embedded semi-
noma tissues, different from those reported in table 1,
were available at the Regina Elena Cancer Institute for
immunohistochemistry experiments. In the latter, the
normal peritumoral tissue was used as control.
Extraction and analysis of mRNA
Normal and tumor tissue samples were homogenized in
Trizol reagent by the ultra-turrax, and total RNA was
extracted with the acid guanidinium thiocyanate-phenol-
chloroform method [29]. The purity and integrity of the
RNA preparations were checked spectroscopically and byUlisse et al. BMC Cancer 2010, 10:151
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agarose gel electrophoresis before carrying out the ana-
lytical procedures. Two-four μg of total RNA were
reverse-transcribed and the obtained cDNAs used as a
template for the subsequent quantitative PCR amplifica-
tions of the different components of the urokinase plas-
minogen activating system with human β-actin as
internal control, using specific primers described in Table
2. Controls for DNA contamination were performed
omitting the reverse transcriptase or the RNA during
reverse transcription. Quantitative PCR assay was per-
formed with the LightCycler instrument (Roche Diagnos-
tics), employing the FastStart DNA Master SYBR Green I
Kit (Roche Applied Sciences). The reactions were set up
in a final volume of 20 μl containing heat-activatable Taq
polymerase, 0.5 μM specific primers and 1.25 ng of tem-
plate. Following polymerase activation (95°C for 10 min),
40 cycles were run with 10 s denaturation at 95°C, 10 s
annealing at optimal temperatures for each primers pair
and 25 s extension at 72°C. All samples were processed in
triplicate and PCR-grade water was used as negative con-
trol. Standard run curves were generated for each gene
using 5 serial dilutions of a cDNA mixture expressing all
the genes analyzed. The results were analyzed at the end
of the run with the LightCycler software, version 1.5
(Roche Diagnostic). In each sample the threshold cross-
ing points (Ct) of target genes were normalized against
that of β-actin, used as reference gene, by the ΔΔCt
method using the LightCycler relative quantification soft-
ware 1.0 (Roche Diagnostics). The values of normalized
target genes in seminoma samples were divided by the
Table 1: Classification of normal and tumor samples analyzed in the present study. n.a., not available.
Sample ID Source Histology Patient's age Tumor size (cm) Stage
1 BioChain Inst. normal 28 - -
2 BioChain Inst. normal 28 - -
3 Regina Elena 
Cancer Inst.
normal 25 - -
4 Regina Elena 
Cancer Inst.
normal 24 - -
5 Regina Elena 
Cancer Inst.
normal 26 - -
6 Regina Elena 
Cancer Inst.
normal 41 - -
7 BioChain Inst. seminoma 41 8 n.a.
8 BioChain Inst. seminoma 24 5 n.a.
9 BioChain Inst. seminoma 44 4 n.a.
10 BioChain Inst. seminoma 30 n.a. n.a.
11 BioChain Inst. seminoma 34 10 n.a.
12 BioChain Inst. seminoma 43 2 n.a.
13 Regina Elena 
Cancer Inst.
seminoma 24 1 pT2
14 Regina Elena 
Cancer Inst.
seminoma 25 5 pT2
15 Regina Elena 
Cancer Inst.
seminoma 55 6 pT2
16 Regina Elena 
Cancer Inst.
seminoma 26 2 pT2
17 Regina Elena 
Cancer Inst.
seminoma 30 3 pT1
18 Regina Elena 
Cancer Inst.
seminoma 41 4 pT1
19 Regina Elena 
Cancer Inst.
seminoma 27 3 pT2
20 Regina Elena 
Cancer Inst.
seminoma 30 6 pT1Ulisse et al. BMC Cancer 2010, 10:151
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average value of normalized target genes found in 6 nor-
mal testicular tissue samples, and reported as fold of vari-
ation. All PCR products were analyzed on 2% agarose gel,
and to determine the specificities of amplified cDNAs
they were recovered from the gel, purified with a gel
cleanup kit and subjected to sequencing reactions in
presence of fluorescent-labelled nucleotides, then ana-
lyzed by ABI Prism 377™ DNA sequencer (Perkin Elmer).
All the obtained sequences corresponded to the expected
ones (data not shown).
Western blot
Three normal matched seminoma tissues were homoge-
nized in RIPA buffer (50 mM Tris-HCl pH 7.4, 1% NP-40,
0.5% sodium deoxycholate, 150 mM sodium chloride, 1
mM EDTA, 1 mM sodium fluoride, 1 mM AEBSF, 10 μg/
ml aprotinin, 10 μg/ml leupeptin, 1 mM sodium orthova-
nadate, 10 mM sodium pyrophosphate in ddH2O) by
ultra-turrax, sonicated and centrifuged at 10.000 rpm for
10 min. The supernatants were then recovered and pro-
tein concentrations determined by the Bradford assay
[ 3 0 ] .  A l i q u o ts  o f  5 0  μ g  o f  t is s u e  e x t r a c ts  w e r e  s u p p l e -
mented with 5× Laemmli buffer (120 mM Tris-HCl, pH
6.8, 2% SDS, 10% Glycerol, 0.01% Bromophenol Blue) and
β-mercaptoethanol 0.2% (w/v), heated at 95°C for 5 min.,
electrophoresed on a 12.5% polyacrylamide gel and trans-
ferred onto nitrocellulose membranes using the Biorad
Mini Trans-Blot Cell system. The membranes were then
washed with TBST (50 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 0.05% Tween-20) and saturated with 5% low fat
milk in TBST for 2 h at room temperature. Incubations
with primary antibodies were performed for the identifi-
cation of uPA and uPAR in 2.5% low fat milk in TBST at
4°C overnight. The monoclonal antibodies raised against
uPA (1:1000) and uPAR (1:250) were detected with anti-
mouse (1:1000) horseradish peroxidase-conjugated sec-
ondary antibody. Samples loadings in the different west-
ern blots were controlled with the monoclonal anti-actin
antibody (1:500). The native human urokinase was used
as positive control.
Substrate gel electrophoresis (zymogram)
Fragments of three normal matched seminoma tissue
samples were homogenized in RIPA buffer without serine
proteases inhibitors by ultra-turrax, sonicated and centri-
fuged at 10.000 rpm for 10 min. Protein concentrations in
the supernatants were determined by the Bradford assay.
Fifty μg of tissue extracts were added to 5× zymography
sample buffer (0,4 M Tris, pH 6.8, 5% SDS, 20% glycerol,
0.03% bromophenol blue) and electrophoresed on a SDS-
polyacrylamide gel containing 0.1% casein plus 12 μg/ml
plasminogen as described [31]. After the electrophoretic
run, the gel was rinsed once in 50 mM Tris-HCl (pH 7.4)
with 2% Triton X-100 and further washed in 50 mM Tris-
HCl (pH 7.4). To detect the activity of the plasminogen
activators, the gel was incubated at 37°C for 4 h in a buffer
containing 50 mM Tris-HCl (pH 7.4) and 0.1% Triton X-
100. An identical gel was incubated in the above buffers
containing 10 μM aprotinin and 1 mM PMSF in order to
assess the enzymes specificity. Finally, the gels were
stained with a solution of 0.1% Coomassie brilliant blue in
25% methanol and 7% acetic acid, and destained in the
same mixture without dye. Clear zones against the blue
background indicated the presence of proteolytic activity.
Samples lytic bands were compared with the supernatant
of the breast cancer cell line MDA-MB-231, known to
secrete both urokinase and tissue type PAs [32]. The
molecular weights of each band were evaluated in com-
parison with a prestained protein ladder using the
UVIPRO GEL Documentation System (Eppendorf).
Immunohistochemical (IHC) analysis
Two μm thick paraffin-embedded sections were treated
with trypsin at 37°C for 30' or with citrate buffer (pH 6)
for uPA and uPAR antigen retrieval, respectively. Sections
were then incubated for 60' at room temperature with
Table 2: Primers, genomic positions, size of amplified products and annealing temperatures used in the PCR for the 
different components of the urokinase plasminogen activating system.
Gene Primers Exon Size (bp)          Tann.
uPA forward 5'-GCCATCCCGGACTATACAGA-3'
reverse 5'-AGGCCATTCTCTTCCTTGGT-3'
8
10
417 60°C
uPAR forward 5'-CTGGAGCTGGTGGAGAAAAG-3'
reverse 5'-TGTTGCAGCATTTCAGGAAG-3'
3
5
406 60°C
PAI-1 forward 5'-ATACTGAGTTCACCACGCCC-3'
reverse 5'-GTGGAGAGGCTCTTGGTCTG-3'
3-4
5-6
320 62°C
PAI-2 forward 5'-GGCCAAGGTGCTTCAGTTTA-3'
reverse 5'-GGGATTTTGCCTTTGGTTTG-3'
2-3
5-6
384 62°C
β-Actin forward 5'-CAAGAGATGGCCACGGCTGCT-3'
reverse 5'-TCCTTCTGCATCCTGTCGGCA-3'
3
4
275 62°CUlisse et al. BMC Cancer 2010, 10:151
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anti-uPA antibody or overnight with anti-uPAR antibody.
Sections were stained with a streptavidin enhanced
immunoperoxidase technique (Supersensitive Multilink,
Novocastra, Menarini Florence, Italy), slightly counter-
stained with Mayer's haematoxylin and mounted in aque-
ous mounting medium (Glycergel, Dako, Milan, Italy).
Immunostained slides were analyzed and scored inde-
pendently by two investigators (MM, ADB). Concerning
uPA and uPAR IHC scoring, seminomas with a missing
staining pattern (0) or with a faint immunostaining (1+)
for both antigens were classified as negative. Seminomas
showing a distinct and intense cytoplasmic immunostain-
ing (2+/3+) were scored as positive regardless of the per-
centage of stained cells.
Statistical analysis
The results are expressed as the mean ± SEM of at least
three independent experiments. Statistical significance of
the expression at mRNA and protein level of the different
components of the uPAS in tumor tissues versus normal
tissues were evaluated by the non parametric Wilcoxon
rank sum test using the Epistat computer program.
Results from the immunohistochemistry experiments
were analyzed by the Fisher's exact test. Correlations
between the fold of increase of uPA or uPAR mRNA and
tumor size, represented by the major diameter of the
lesion, or patient age were evaluated by the non paramet-
ric Spearman correlation test using the SPSS software
(SPSS Inc., Chicago, Ill.). Results were determined to be
significantly different if p values were lower than 0.05.
Results
We first evaluated the mRNA levels of the different com-
ponents of the urokinase plasminogen activating system
(uP AS) in 14 seminoma tissues in comparison to those
observed in 6 normal testicular tissues. Quantitative RT-
PCR analysis showed significant (p < 0.01) increases for
uPA mRNA by 3.80 ± 0.74 fold, and uPAR mRNA by 6.25
± 1.18 fold in tumor tissues with respect to normal tissues
(figure 1). The level of PAI-1 mRNA was not significantly
changed (1.02 ± 0.24 fold), while PAI-2 mRNA level was,
with respect to control tissues, significantly reduced in
seminomas to 0.34 ± 0.18 fold (p < 0.01) (figure 1). The
increased expression of uPA could be confirmed at pro-
tein level by means of western blot and zymographic
analysis on protein extracts from three available normal
matched seminomas. In fact, as reported in figure 2A,
western blot experiments showed that uPA protein levels
were very low or undetectable in normal tissues and
strongly induced in tumor tissues. The enzymatic activity
of the plasminogen activators (PAs) present in normal
matched tumor tissue protein extracts was evaluated by
zymographic analysis, in comparison to that exhibited by
the supernatant of the breast cancer cell line MDA-MB-
231, known to secrete both urokinase and tissue type PAs
[29]. The results reported in figure 2B revealed aug-
mented uPA activity in tumor tissue extracts with respect
to the control ones. On the other hand, tPA activity could
not be documented either in normal or tumor samples
(figure 2B). Incubation of gel with PMSF and aprotinin
abrogated all enzyme activities (data not shown). In addi-
tion, the increased expression of uPAR could be con-
firmed at protein level in three normal matched tumor
tissue extracts by means of western blot, as reported in
figure 2C. Densitometric analysis of the immunoreactive
bands showed a significant increase of the uPAR protein
in tumor tissues by 1.83 ± 0.15 fold (p < 0.01), with
respect to control tissues.
IHC staining, performed on 10 human seminomas,
showed no uPA reactivity in the autologous normal testis
surrounding the tumor (panel A, figure 3), while an
intense uPA immunoreactivity was evidenced (score 2+/
3+) in 3 out of 10 (30%) samples (p = 0.105) (panel C, fig-
ure 3). Staining of uPAR was appreciated in 3 out of 10
normal tissues (30%). In the latter, Sertoli cells appeared
to be positive, while the spermatogonia were negative
(panel B, figure 3). An intense and homogeneous uPAR
immunoreaction (score 2+/3+) was present in 9 (90%)
seminomas out of 10 (p < 0.05) (panel D of figure 3). It
may be worth mentioning that the single uPAR negative
sample showed a strong uPA immunoreactivity. A nega-
tive control for seminoma tissue is reported in panel E of
figure 3.
Figure 1 Messenger RNA levels of the uPAS components in 14 hu-
man seminomas analyzed by quantitative RT-PCR. Fold of varia-
tions for uPAS components mRNAs in seminoma tissues have been 
calculated considering equal to 1 the mean value of uPAS component/
β-Actin ratios found in 6 normal testicular tissues. The bars reported in 
the figure represent the median values. *p < 0.01.
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We then sought to verify whether uPA, uPAR, PAI-1 or
PAI-2 mRNAs expression in tumor tissues correlated
with patient's age (n = 14), TNM stage (n = 8, 3 pT1 and 5
pT2) or tumor size (n = 13) (Table 1). As shown in figure
4, among the different uPAS components only PAI-1 sig-
nificantly correlated with tumor size (p < 0.05), while
none of them correlated with patient's age. Finally, none
o f  t h e  u P A S  c o m p o n e n t s  c o r r e l a t e d  w i t h  T N M  s t a g e
(data not shown).
Discussion
Human cancers progression is characterized by malig-
nant cells acquisition of novel functional competences
which include self-sufficiency in growth signals, insensi-
tivity to anti-growth signals, evasion of apoptosis, limit-
less replicative potential, sustained angiogenesis and
tissue invasion and metastasis [33]. The aberrant expres-
sion of uPAS components in malignant tissues contrib-
utes to the acquisition of some of these new cell
capabilities. In fact, beside its role in ECM degradation
allowing tumor progression and metastasis, extensive
experimental evidence demonstrated the capability of the
uPAS to affect tumor cell proliferation, adhesion and
migration, intravasation and extravasation, growth at the
metastatic sites and tumor neoangiogenesis [11,16,17].
The involvement of uPAS in cancer progression and the
observation that its inhibition is devoid of toxicity, as
demonstrated in uPA or uPAR deficient mice, identifies
the uPAS as a suitable target for anti-cancer therapies
[11,16,17,26]. Despite that, few information are available
on the expression and function of uPAS components in
Figure 2 Western blot analysis of uPA (A) and uPAR (C) and zymo-
graphic analysis (B) of 3 normal matched seminoma cancer tis-
sues. Fifty μg of the different tissue protein extracts were loaded in 
each lane and subjected to western blot as described in the Methods 
section, using specific monoclonal antibodies against uPA (panel A), 
uPAR (panel C) and β-actin as protein loading control. In panel B, is re-
ported the zymographic analysis of the uPA activity in protein tissues 
extracts of 3 normal matched seminoma cancer tissues. The condi-
tioned medium of human breast carcinoma cell line MDA-MB-231 has 
been used as positive control for urokinase and tissue type PA activity, 
as described in the Materials and Methods section. Data reported rep-
resents one out of three similar experiments.
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Figure 3 Immunohistochemistry analysis of uPA and uPAR ex-
pression in human testicular germ cell tumor. Tissue sections from 
10 cases of seminomas were incubated with antibodies against hu-
man uPA or uPAR and processed as described in the Methods section. 
A) A representative normal testis stained with uPA antibody. B) A rep-
resentative normal testis stained with uPAR antibody. C) A representa-
tive seminoma stained with uPA antibody. D) A representative 
seminoma stained with uPAR antibody. E) Negative control for semi-
noma tissue obtained omitting the first antibody. Tissue sections were 
counterstained with Mayer hematoxylin. Scale bar = 30 μm.
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Figure 4 Correlation analysis between tumor size or patient's age and uPA or uPAR mRNA variations. Folds of mRNA variations in seminomas 
versus normal tissues were calculated as described in Materials and Methods section. The correlation analysis between uPA or uPAR mRNA variations 
and tumor size or patient's age were performed by the Spearman correlation test.
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the progression of testicular germ cell tumors (TGCT)
[3,27,28,34]. In particular, Okada and colleagues, by
means of laser-capture microdissection and a genome-
wide cDNA microarray, found the uPA gene (PLAU)
among the 347 genes commonly up-regulated in semi-
noma cells, with respect to normal human testis [28]. In
similar studies, the PLAU gene expression was found,
with respect to normal testicular tissues, unchanged in
the intratubular germ cell neoplasia (IGCN), but signifi-
cantly augmented in TGCT [3,34]. In the same studies, it
was also shown that the expression of the PAI-1 gene did
not change significantly in the TGCT [3,34]. These obser-
vations are in agreement with the data here reported
showing the up-regulation of uPA, but not PAI-1, mRNA
in seminomas, with respect to normal testis. The
increased expression of uPA was further documented by
means of western blot and zymographic analysis of pro-
tein extracts from three normal matched tumor tissues.
Moreover, we here demonstrated that also the expression
of the uPA receptor (uPAR) was significantly increased in
seminomas, at both protein and mRNA levels. On the
contrary, we found that the expression of PAI-2 gene was
significantly reduced in tumor tissues. The latter findings
are in partial agreement with the observation of Konaka
and colleagues which demonstrated, in a human semi-
noma xenograft model, the increased expression of uPA,
uPAR and PAI-1, and a decreased expression of PAI-2 in
testicular xenograft, with respect to subcutaneous xeno-
graft [27]. The expression at the mRNA level of PAI-2 has
been associated to a good prognosis in several cancer
types such as breast, head and neck, esophageal and pan-
creatic cancers, and with a poor prognosis in others as
endometrial, cervical and colorectal cancer. The latter
may be due to the fact that the majority of PAI-2 protein
is not secreted but retained in the cells, where it may have
a role in protecting the cells from apoptotic stimuli (i.e.
TNF-α) [9,10,35,36]. However, the prognostic relevance
of PAI-2 in TGCT remains to be investigated.
The immunohistochemical (IHC) analysis revealed, in
normal testis surrounding the tumor, that Sertoli cells
were weakly positive for uPA and more strongly for
uPAR, while spermatogonia were negative for both uPA
and uPAR. These observations are in agreement with a
previous study reporting the expression of uPA within
normal human testis [37]. In the latter, uPA immunoreac-
tivity was detectable in Sertoli cells and in some Leydig
cells, but not in spermatogonia [37]. The IHC analysis of
tumor tissues confirmed mRNA and protein data
obtained by means of RT-PCR and western blot. In fact,
we found a statistically significant increase of uPAR pro-
tein expression in seminoma with respect to the autolo-
gous normal testis surrounding the tumor. Also uPA
immunoreactivity was found increased in seminoma tis-
sues with respect to normal testis, but the increase did
not reach the statistical significance.
Among the implications of the enhanced uPA expres-
sion and activity, strengthened by the concomitant uPAR
increase and PAI-2 reduction, is the potential activation
by plasmin of latent MMPs, such as proMMP-1,
proMMP-2, proMMP-3, proMMP-9, proMMP-10 and
proMMP-13. In fact, several MMPs, including MMP-9,
show an increased expression in TGCT and, along with
plasmin, they might contribute to release or activate
ECM-associated mitogenic, motogenic and angiogenic
growth factors, including bFGF, VEGF, HGF, IGFs, EGF
and TGF-β [3,8,11,16,17,19-21,26,28,38].
Consistent with its role in cancer progression, a strong
correlation between the overexpression of one or more
uPAS components and the poor clinical outcome in sev-
eral types of human cancer has been documented
[8,11,16,17,39]. In the present study we found that among
the uPAS components only PAI-1 significantly correlates
with tumor size, while none of them correlates with
patient's age or TNM stage. Increased PAI-1 expression
has been associated with poor prognosis in several
human malignancies, however, since this analysis has
been performed on a small number of patients, larger
case studies are needed to prove that PAI-1 expression
may represent a negative prognostic marker also in
human seminoma.
Conclusions
In conclusion, we demonstrated that testicular germ cell
tumors are characterized by increased expression of uPA
and uPAR and concomitant reduced expression of PAI-2.
This could be of relevance in seminoma progression pro-
moting local diffusion and spread to distant sites.
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